Opendata, web and dolomites

HEPCAN SIGNED

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEPCAN project word cloud

Explore the words cloud of the HEPCAN project. It provides you a very rough idea of what is the project "HEPCAN" about.

recurrence    triggers    symptoms    amounted    keep    fibrosis    accelerate    steatohepatitis    iarc    primary    first    medical    continual    frequent    usually    therapy    aggressive    populations    absence    recommended    sorafenib    carcinoma    deaths    population    systemic    validate    prognosis    suggesting    2018    months    heterogeneity    damaging    prolonging    compound    resistance    poor    benefit    leads    livers    diagnosis    fatty    alcoholism    tumor    rising    fda    constrains    hepatocellular    approved    375    mortality    medicine    liver    worldwide    therapeutic    monotherapy    alcoholic    screening    combination    resistant    77    persistent    cirrhotic    drugs    viruses    cells    nature    reaching    cancer    inappropriate    stages    80    consequently    valuable    survival    drug    molecules    option    2040    curative    sub    owing    trigger    hepatitis    precision    cell    fibrotic    experiencing    hcc    patients    causes    treatment    unmet    resection    progression    efficacy    disease    amongst    urgent    fact    closely   

Project "HEPCAN" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

Hepatocellular carcinoma is the most frequent primary liver cancer and owing to its very aggressive nature is amongst the leading cause of cancer mortality worldwide (IARC). The number of liver cancer-related deaths in Europe in 2018 amounted to 77 375, and this number is expected to keep rising, reaching an estimated number of more than 100 000 deaths in 2040 (IARC). Major causes include the hepatitis B and C viruses, alcoholism, Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. All of these medical conditions trigger liver fibrosis by damaging the liver and are closely associated with the development of HCC. As a matter of fact, more than 80% of HCC develop in fibrotic or cirrhotic livers. Early stages of liver cancer do not usually produce symptoms, and many challenges are associated with the screening of HCC, leading to its late diagnosis. The absence of effective drug treatment for HCC makes its resection the first curative option with most of the patients experiencing HCC recurrence within 5 years. All these factors contribute to the poor prognosis of the HCC patients. Sorafenib is the only currently approved systemic therapy for advanced HCC in the EU, only prolonging survival by an average of 3 months, the treatment often leads to drug resistance. Indeed, intra-tumor heterogeneity strongly constrains the therapeutic benefit of precision medicine and triggers drug-resistant sub-population of cells. Consequently, persistent treatment of drug-resistant tumor cells may accelerate tumor progression, suggesting that inappropriate and continual use of a compound on drug-resistant cancer cells is not recommended. Thus, there is an urgent unmet medical need to identify and to validate the therapeutic efficacy of new valuable molecules – i.e. targeting the existing drug-resistant cell populations -that could be used in monotherapy or in combination therapy with FDA-approved drugs to improve HCC treatment responses.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEPCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MATCH (2020)

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research

Read More  

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

BECAME (2020)

Bimetallic Catalysis for Diverse Methane Functionalization

Read More